Published in Arthritis Res Ther on July 08, 2014
Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement | NCT00573326
Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res Ther (2015) 0.85
Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol (2015) 0.83
Current perspectives on the immunopathogenesis of systemic sclerosis. Immunotargets Ther (2016) 0.79
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.78
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Ann Am Thorac Soc (2016) 0.78
Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int (2017) 0.78
Mastocytosis and systemic sclerosis: a clinical association. Clin Mol Allergy (2016) 0.75
Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations. Dis Markers (2016) 0.75
Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro. Front Immunol (2017) 0.75
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Optimal two-stage designs for phase II clinical trials. Control Clin Trials (1989) 21.03
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J (2005) 7.58
Standardisation of the measurement of lung volumes. Eur Respir J (2005) 7.48
Scleroderma. N Engl J Med (2009) 6.50
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov (2002) 6.13
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis (2007) 4.88
Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol (1995) 4.11
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
Randomized phase II clinical trials. Cancer Treat Rep (1985) 3.19
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) (2002) 2.86
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest (2006) 2.10
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood (2004) 2.01
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood (2005) 1.80
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum (2011) 1.70
High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol (2006) 1.68
Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis (2013) 1.51
Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review. Clin Rheumatol (2012) 1.43
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum (2005) 1.42
Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum (2011) 1.36
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis (2011) 1.20
Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology (1990) 1.13
Interstitial lung disease in scleroderma. Rheum Dis Clin North Am (2003) 0.98
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol (2012) 0.96
The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol (2006) 0.92
Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J Clin Immunol (2011) 0.91
Imatinib: novel treatment of immune-mediated kidney injury. J Am Soc Nephrol (2013) 0.83
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med (2009) 4.48
Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med (2006) 4.46
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Management of minor head injury in patients receiving oral anticoagulant therapy: a prospective study of a 24-hour observation protocol. Ann Emerg Med (2012) 3.55
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol (2004) 3.07
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) (2002) 2.86
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res (2006) 2.77
Evidence for a cross-talk between human neutrophils and Th17 cells. Blood (2009) 2.75
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. Clin Exp Rheumatol (2012) 2.56
Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood (2009) 2.51
Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2004) 2.43
IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. Ann Rheum Dis (2012) 2.28
Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med (2007) 2.27
Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol (2012) 2.27
Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: a multicenter study. Am Heart J (2012) 2.05
Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation (2005) 2.03
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int (2007) 2.03
Regional Implantation of Autologous Adipose Tissue-Derived Cells Induces a Prompt Healing of Long-Lasting Indolent Digital Ulcers in Patients With Systemic Sclerosis. Cell Transplant (2014) 2.02
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol (2002) 1.97
Risk of non-Hodgkin lymphoma in celiac disease. JAMA (2002) 1.81
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77
Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol (2007) 1.75
Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol Med (2010) 1.72
Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J Immunol (2007) 1.70
Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet (2003) 1.64
Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. Heart (2010) 1.61
Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood (2007) 1.60
Effects of shock wave therapy in the skin of patients with progressive systemic sclerosis: a pilot study. Rheumatol Int (2010) 1.59
Helicobacter pylori serology in autoimmune diseases - fact or fiction? Clin Chem Lab Med (2013) 1.56
Microcirculatory effects of the transfusion of leukodepleted or non-leukodepleted red blood cells in patients with sepsis: a pilot study. Crit Care (2014) 1.56
Endosomal compartment contributes to the propagation of CD95/Fas-mediated signals in type II cells. Biochem J (2008) 1.53
Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res (2002) 1.52
Stress Doppler echocardiography in systemic sclerosis: evidence for a role in the prediction of pulmonary hypertension. Arthritis Rheum (2013) 1.51
Classification criteria for Sjogren's syndrome: a critical review. J Autoimmun (2011) 1.46
Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis (2010) 1.45
Isolated aortitis versus giant cell arteritis: are they really two sides of the same coin? Clin Exp Rheumatol (2014) 1.43
The effect of sex/gender on cardiovascular pharmacology. Curr Pharm Des (2011) 1.41
Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol (2013) 1.41
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
Role of viral infections in the etiopathogenesis of systemic sclerosis. Clin Exp Rheumatol (2013) 1.40
Epidemiology and management of neuropsychiatric disorders in Behçet's syndrome. CNS Drugs (2015) 1.39
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis (2011) 1.37
Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol (2003) 1.36
In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med (2006) 1.34
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum (2006) 1.30
Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc Natl Acad Sci U S A (2007) 1.29
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis (2014) 1.27
Foot involvement in systemic sclerosis: a longitudinal study of 100 patients. Semin Arthritis Rheum (2002) 1.27
Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol (2012) 1.27
Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am (2010) 1.26
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev (2011) 1.26
Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem (2005) 1.26
Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum (2005) 1.25
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood (2013) 1.24
A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet (2011) 1.24
Proteome analysis of whole saliva: a new tool for rheumatic diseases--the example of Sjögren's syndrome. Proteomics (2007) 1.23
Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev (2011) 1.23
Are the available experimental models of type 2 diabetes appropriate for a gender perspective? Pharmacol Res (2007) 1.22
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis (2012) 1.21
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev (2012) 1.21
Role of the interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune disorders. Ann N Y Acad Sci (2007) 1.21
The microenvironment can shift erythrocytes from a friendly to a harmful behavior: pathogenetic implications for vascular diseases. Cardiovasc Res (2007) 1.20
Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol Lett (2010) 1.19
Cardiolipin-enriched raft-like microdomains are essential activating platforms for apoptotic signals on mitochondria. FEBS Lett (2009) 1.19
Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus. FASEB J (2012) 1.18
Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum Mol Genet (2012) 1.17
Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem (2004) 1.17
Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest (2003) 1.17
Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol (2005) 1.16
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
Ultrasound lung comets in systemic sclerosis: a chest sonography hallmark of pulmonary interstitial fibrosis. Rheumatology (Oxford) (2009) 1.16